Valuation: Insulet Corporation

Market Cap 10.41B 9.38B 8.67B 7.83B 14.82B 976B 15.19B 104B 41.4B 523B 39.06B 38.23B 1,664B P/E 2026 *
23x
P/E 2027 * 18.7x
Enterprise Value 11.07B 9.98B 9.22B 8.34B 15.77B 1,039B 16.16B 111B 44.04B 556B 41.56B 40.67B 1,770B EV / Sales 2026 *
3.35x
EV / Sales 2027 * 3.04x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+1.33%
1 week-9.08%
Current month+0.23%
1 month+10.90%
3 months+3.68%
6 months-2.69%
Current year-47.22%
1 week 143.28
Extreme 143.282
155.6
1 month 133.58
Extreme 133.58
168.47
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 126.4
Extreme 126.4
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 32.12
Extreme 32.12
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Director/Board Member 61 27/07/2015
Director/Board Member 54 20/10/2020
Director/Board Member 55 18/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Tax

Chief Financial Officer

-1,882 0.0027%
30/9/26 Free

Director

141 0.0002%
30/9/26 Free

Director

178 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+1.33%-9.08%-54.02%-3.27% 10.27B
-1.06%-5.38%-13.94%+16.30% 191B
+0.02%-3.19%+6.51%+43.76% 124B
-1.70%-6.14%-12.35%+16.51% 123B
-2.69%-3.46%-42.12%+4.37% 96.14B
+0.34%-1.16%-4.16%+77.09% 66.54B
+0.90%+2.55%+13.49%-8.58% 57.91B
+0.85%+0.58%-1.39%+63.88% 54.89B
+2.49%+1.58%-0.24%+58.70% 49.1B
-3.88%-6.01%-3.60%-8.41% 36.19B
Average -0.34%-2.34%-11.18%+26.04% 81B
Weighted average by Cap. -0.68%-2.96%-9.51%+26.79%

Financials

2026 *2027 *
Net sales 3.3B 2.98B 2.75B 2.49B 4.71B 310B 4.82B 32.98B 13.14B 166B 12.4B 12.14B 528B 3.69B 3.33B 3.07B 2.78B 5.26B 346B 5.39B 36.84B 14.68B 185B 13.85B 13.56B 590B
Net income 455M 410M 379M 342M 648M 42.65B 664M 4.54B 1.81B 22.84B 1.71B 1.67B 72.69B 535M 482M 445M 403M 762M 50.15B 780M 5.34B 2.13B 26.86B 2.01B 1.96B 85.48B
Net Debt 666M 600M 554M 501M 948M 62.44B 971M 6.64B 2.65B 33.44B 2.5B 2.45B 106B 808M 728M 672M 608M 1.15B 75.74B 1.18B 8.06B 3.21B 40.56B 3.03B 2.97B 129B
Projected Income Statement - Annual - Insulet Corporation
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
11/11/26 USD 150.03 +1.33% 1,042,735
10/11/26 USD 148.06 -1.17% 1,077,220
09/11/26 USD 149.81 +2.25% 1,332,171
06/11/26 USD 146.51 -6.16% 1,568,169
05/11/26 USD 156.12 -5.39% 1,319,327
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Insulet Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
150.03USD
Average target price
178.57USD
Spread / Average Target
+19.02%
  1. Stock Market
  2. Stocks
  3. PODD Stock